FIG 3.

Screening of potential drug-like compounds selected by a computer-aided drug design approach to block the binding of ACE2: SARS-CoV-2 Spike receptor-binding domain (RBD). MU-UNMC-1, MU-UNMC-2, MU-UNMC-6, MU-UNMC-7, and MU-UNMC-8 were tested at different concentrations in triplicate starting from 0.25 to 5 μM to evaluate their ability to inhibit binding of SARS-CoV-2 Spike RBD to immobilized human ACE2 using an ELISA as described in materials and methods. The IC₅₀ values were computed using four-parameter variable slope sigmoidal dose-response models using Graph Pad Prism 8.0 software.